Sales of Replagal agalsidase alfa from Shire plc (LSE:SHP; NASDAQ:SHPGY) have increased nearly 150% since Genzyme Corp., maker of competitor product Fabrazyme agalsidase beta, began having manufacturing problems in 2009. Sales of Replagal, which is